Journal of the Endocrine Society Journal Article

Growth Hormone Replacement in Craniopharyngioma: Analysis of the Hypopituitary Control and Complications Study (HypoCCS)

June 24, 2025
 

Odelia Cooper and Sungjin Kim
Journal of the Endocrine Society, Volume 9, Issue 6, June 2025, bvaf072
https://doi.org/10.1210/jendso/bvaf072

Abstract

Context

Patients with adult-onset craniopharyngioma (CP) show metabolic dysfunction and panhypopituitarism. Growth hormone (GH) deficiency is often left unaddressed despite the benefits of GH replacement on body composition and lipoprotein metabolism in the general population.

Objective

The aim was to analyze data from Hypopituitary Control and Complications Study (HypoCCS), a global prospective surveillance study of adult GH replacement, and assess the impact of GH replacement on metabolic outcomes in adult-onset CP.

Methods

Primary outcome was a composite endpoint of adverse hepatic outcomes including metabolic dysfunction-associated steatotic liver disease; secondary outcomes included body composition, lipids, blood pressure, glycemic measures, mortality, bone density, and cardiovascular endpoints.

Results

In total, 592 patients with adult-onset CP were identified; 544 received GH for a median of 4.03 years (IQR 2.28–7.82). The 3972 patients with pituitary adenoma (3346 receiving GH) were analyzed for context. GH replacement did not impact hepatic outcomes in either cohort. In adult-onset CP, bone mineral content was significantly lower with GH replacement (estimated mean [est]: 324.90 g; 95% CI −574.49, −75.31; P = .034); lower waist–hip ratio and less dyslipidemia medication use were also seen. In pituitary adenomas, fasting blood glucose (est 6.45; 95% CI 3.24, 9.66; P < .001), diastolic blood pressure (est 1.44; 95% CI 0.45, 2.43; P = .005), and mean arterial pressure (est 1.20; 95% CI 0.14, 2.26; P = .027) were significantly higher.

Conclusion

GH led to decreased waist–hip ratio and lipid medication use but adversely impacted bone mineral content in adult-onset CP. Prospective studies of GH replacement in adult-onset CP can further define the benefits on metabolic outcomes in these patients.

Read the article

 

You may also like...

Publishing Benefits

Author Resource Center

We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.
Publishing Benefits

Author Resource Center

We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.

Thematic Issue

Latest Thematic Issue

immuno-endocrinology
Read our special collections of Endocrine Society journal articles, curated by topic, Altmetric Attention Scores, and Featured Article designations.

Read our special collections of Endocrine Society journal articles, curated by topic, Altmetric Attention Scores, and Featured Article designations.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.